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High dose intensity combination chemotherapy for advanced epithelial
ovarian carcinoma: results of a pilot study
J.W. Sweetenham, J.J. McKendrick, D.H. Jones, J.M.A. Whitehouse & C.J. Williams
CRC Wessex Medical Oncology Unit, Southampton General Hospital, Tremona Road, Southampton S09 4XY, UK.
Summary Retrospective studies have recently demonstrated a significant correlation between dose intensity of
chemotherapy and response rates and survival in various diseases including epithelial ovarian carcinoma. As
part of a proposed randomised trial to assess the effect of dose intensity on outcome in ovarian carcinoma, a
pilot study has been undertaken to determine the toxicity and efficacy of the high intensity therapy. Nineteen
patients with advanced ovarian carcinoma received initial treatment with cisplatin 120 mg m2 i.v. day 1, and
cyclophosphamide 1,000 mg 2 i.v. day 1, given at 21-day intervals for six cycles. The average relative dose
intensity of this therapy is 1.14 when compared with the CHAP regimen. Severe toxicity was experienced by
most patients. The median received average relative dose intensity was 0.90, with only one patient receiving
treatment to the proposed intensity. Randomised studies of the effect of dose intensity in ovarian carcinoma
are essential, but an initial step must be to assess whether the proposed high dose treatment can be delivered.
Cisplatin-based chemotherapy is widely accepted as the stan-
dard treatment for advanced epithelial ovarian carcinoma. It
produces higher response rates compared with single
alkylating agents, although its effect on survival is less clear
(Gynaecological Group: Clinical Oncology Society of Aust-
ralia, 1986; Bruckner et al., 1981; Decker et al., 1982; Wil-
liams et al., 1985; Vogl, 1983). In recent studies, high dose
chemotherapy regimens (mainly with cisplatin) have been
used in an attempt to improve response rates (Ozols et al.,
1985). Such intensive regimens are associated with con-
siderable toxicity, often requiring long periods of inpatient
care. It is therefore essential that such regimens are compared
with less intensive therapy in a systematic fashion.
Levin and Hryniuk (1987) have analysed dose intensity
(dose per unit time) in studies of chemotherapy in ovarian
cancer and have suggested a correlation between dose inten-
sity, response rate and median survival. An apparent survival
advantage was demonstrated for combination chemotherapy
(especially cisplatin based) compared with single agents. The
significance of the correlation is unclear since the study was
retrospective and many of the patients included in the trials
were highly selected. In addition, the analysis of dose inten-
sity was based upon the planned and not the received dose
intensity.
For these reasons we decided to undertake a prospective
randomised study to test the effect upon survival of
chemotherapy with cisplatin and cyclophosphamide at two
dose intensities, but to the same total dose, in patients with
advanced ovarian carcinoma. Before this, we decided to carry
out a phase II study of the high dose intensity chemotherapy
in an unselected patient population. Our aims were to assess
its toxicity and to determine whether the planned dose inten-
sity could be attained.
Patients and methods
Patients
Patients were entered into this study from September 1987
until February 1989.
Eligibility criteria were as follows: histologically confirmed
epithelial ovarian carcinoma; age 15-75; Karnofsky perfor-
mance status >50%, FIGO stage II with >2 cm residual
disease, or FIGO stage III and IV; normal full blood count,
serum biochemistry and creatinine clearance. Patients were
ineligible if they had received prior chemotherapy or
radiotherapy, had a history of prior malignancy (except for
basal cell or squamous cell carcinoma of the skin), had a
history of congestive cardiac failure, or if they had a pleural
effusion as the only site of advanced disease.
All patients were referred from one of three gynaecologists.
All had undergone a laparotomy at which an attempt was
made to excise completely all visible tumour and perform a
total abdominal hysterectomy, bilateral salpingoophorectomy
and omentectomy. Patients were staged according to the
FIGO system. Diagnostic biopsies were taken in all cases and
histological review was performed by one of two
pathologists. Histological grading was performed according
to the Broder system. Following surgery, baseline assessment
comprised physical examination, a full blood count, serum
biochemistry profile, estimation of creatinine clearance, chest
X-ray, abdominal and pelvic ultrasonography, and com-
puterised tomography of the abdomen and pelvis in selected
patients.
Chemotherapy
Treatment comprised cisplatin 120 mg m-2 i.v. day 1, and
cyclophosphamide 1,000 mgm-2 i.v. day 1, given at 21-day
intervals for a total of six cycles. All patients were admitted
to hospital for treatment. Cisplatin was administered as an
intravenous bolus using a standard pre-hydration and post-
hydration schedule. All received similar anti-emetic treatment
with dexamethasone, lorazapam and domperidone. Mesna
was not routinely given. Since an assessment of received dose
intensity was a main end-point of the study, dose
modifications were adhered to strictly. The following criteria
were used.
1. For haematological toxicity, full doses of both drugs
were given if the day I total white cell count was >3.0 x 109
per litre, and the platelet count >100 x 109 per litre. If the
white cell count was 2.5-2.9 x 109 per litre, or the platelet
count 75-99 x 109 per litre, 50% doses of both drugs were
given. If the white cell count was less than 2.5 x 109 per litre,
or the platelet count less than 75 x 109 per litre, treatment
was delayed and the full blood count repeated at 48-h inter-
vals until sufficient to allow further treatment.
2. For renal impairment, creatinine clearance was deter-
mined from the serum creatinine using the method of Cock-
croft and Gault (1976). If this value was borderline for
treatment (see below), the glomerular filtration rate was
determined by radiolabelled technetium clearance. If the
creatinine clearance was greater than 70 1 24 h-'
(50 ml min-') full dose cisplatin was given. If the creatinine
clearance was 50-701 24 h-' (30-50 ml min-'), 50% of
doses of cisplatin were given. If the creatinine clearance was
less than 50 1 24 h-' 30 ml min-'), cisplatin was omitted.
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Calculation ofaverage relative dose intensity
This was calculated according to the method of Levin and
Hryniuk (1987), using the CHAP regimen, as described by
Greco et al. (1981), as the standard regimen with an average
relative dose intensity (ARDI) of 1. Briefly, the method is as
follows. The dose intensity of individual drugs is calculated
in a standardised form of mg m-2week-'. Each dose inten-
sity is then calculated as a decimal fraction of the intensity of
the respective drug in the standard regimen, giving the
relative dose intensity of each drug. The relative dose inten-
sities are then added and divided by 4 (the number of drugs
in the CHAP regimen) to produce the ARDI. Since the study
regimen has less than four drugs, the two 'missing' drugs are
assigned to relative dose intensity of zero.
Thus, the planned ARDI of the study regimen is:
40/15+330/175+0+0 = 1.14
4
Received ARDIs were calculated by the same method,
accounting for dose reduction and treatment delays. Patients
in whom one or more cycles of treatment were omitted
because of toxicity were still assumed to have a total
treatment period of 18 weeks. However, patients in whom
treatment was omitted because of progressive disease were
assessed on the basis of the actual number of weeks on
treatment, calculated to the date on which the next cycle of
treatment would have been due.
Assessment oftoxicity and response
Toxicities were recorded according to WHO criteria. As well
as alopecia, nausea and vomiting and haematological toxic-
ity, particular attention was paid to renal toxicity, ototoxicity
and peripheral neuropathy.
Response was assessed after two cycles of chemotherapy
and 4 weeks after the completion of chemotherapy. This
included physical examination and repetition of previously
abnormal investigations. Second look laparotomy was not
performed in any patient.
Definition of responses was as follows: complete response,
no clinical or radiological evidence of disease; partial res-
ponse, >50% reduction in the product of the two largest
perpendicular diameters of any measurable lesion; stable
disease, <50% reduction in the product of the two largest
perpendicular diameters of any measurable lesion; progres-
sive disease, increase in measurable disease at known sites or
appearance of new lesions.
oedema of both lower limbs during pre-hydration for her
first cycle of chemotherapy. This was due to inferior vena
cava compression and the patient was treated with alternative
chemotherapy.
In two patients severe toxicity occurred, resulting in dis-
continuation of trial therapy. One patient developed severe
(WHO grade 3) ototoxicity after two cycles of chemotherapy
and was subsequently treated with single agent carboplatin.
The other patient developed severe nausea and vomiting,
grade 3 ototoxicity and profound neutropenia and throm-
bocytopenia after one cycle of treatment. She required int-
ravenous antibiotics for neutropenic sepsis. No further trial
chemotherapy was given. Both these patients are included in
the analysis of received ARDI, with a projected treatment
duration of 18 weeks.
The received ARDI values for these two patient were 0.38
and 0.19 respectively. For the whole group of 18 patients, the
median received ARDI was 0.90 (range 0.19-1.14). Only one
patient received treatment at the planned dose intensity, and
this patient developed progressive disease after five cycles.
The received ARDIs are presented in Figure 1.
Toxicity
A total of 93 cycles of chemotherapy were administered to
the 18 evaluable patients. Fifteen cycles of chemotherapy
were therefore omitted due to toxicity (13 cycles) or pro-
gressive disease (two cycles). Apart from the two patients
mentioned above, who received one and two cycles respec-
tively, all other patients received at least five cycles of
chemotherapy. In two patients, cisplatin was omitted from
cycle 6 because of severe ototoxicity and elevation of serum
creatinine.
The most frequent toxicities were myelosuppression and
renal impairment. In addition to the 13 cycles which were
omitted, six cycles of treatment were delayed or attenuated
due to myelosuppression, 18 due to nephrotoxicity and 14
due to a combination of both.
The values for full blood counts on day 1 of each cycle are
shown in Table II. One patient developed neutropenic sepsis
and associated thrombocytopenia requiring platelet support.
A further patient developed a urinary tract infection, but
with a normal white cell count. Details of nephrotoxicity are
shown with other toxicities in Table III. WHO grade 1 or 2
elevations of serum creatinine occurred in most patients,
although severe, inreversible nephrotoxicity was not seen.
Peripheral neuropathy was particularly common, occurring
in 12 patients. This has persisted over several months in
surviving patients and has been present, but improving, for 9
months after completion of chemotherapy.
Results
Nineteen patients were entered into this study. Details of
their characteristics at presentation are shown in Table I. The
majority presented with FIGO stage III disease. Complete
resection of disease was possible in only four patients.
Of the 19 patients entered, 18 were eligible for measure-
ment of received ARDI. One patient developed severe
Table I Patient characteristics
No. 19
Median age (range) 60 (34-72)
FIGO stage II I
III 15
IV 3
Residual disease bulk
0 4
<2cm 4
>2cm 11
Broder grade
1 1
2 6
3 7
4 2
Unknown 3
I 1
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Received average relative dose intensity
Figure 1 Histogram showing received average relative dose
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Table II Results for full blood count on day I of each cycle
Mean (±s.e.) Median Range
Haemoglobin (gdl') 10.7 (±1.8) 10.5 7.7-15.1
White cell count (x 109 1 1) 4.5 (+ 1.7) 4.2 0.4-9.3
Platelets ( x I0O 11) 414 (± 187) 335 9-817
Table III Summary of other toxicities
No. ofpatients experiencing WHO grade
System 0 1 2 3 4
Alopecia 0 1 1 16 0
Nausea and vomiting 0 0 0 18 0
Serum creatinine 6 7 5 0 0
Infection 16 1 0 1 0
Peripheral neuropathy 6 2 5 5 0
Ototoxicity 6 7 2 3 0
As a result of these toxicities cisplatin dosage was omitted,
modified or delayed in 22 cycles, and both drugs were
omitted, modified or attenuated in 23 cycles. No dose modifi-
cations of cyclophosphamide alone was necessary. Thus,
overall, cisplatin dosage was modified almost twice as
frequency as cyclophosphamide.
Responses
Response data are shown on Table IV. Ten patients achieved
a complete clinical remission, of who four have subsequently
relapsed. Of those achieving a partial remission one has
subsequently developed progressive disease, and both patients
who were stable on chemotherapy have had progressive
disease and died.
Table IV Summary of responses
Response No.
CR 10
PR 2
SD 2
PD 2
Inevaluable 2
With a median follow up of 7 months (range 3-15), seven
patients remain in complete remission, six are alive but with
clinical or radiological evidence of progressive disease, and
six patients have died of disease.
Discussion
The potential influence of dose intensity upon outcome was
reported for patients receiving adjuvant chemotherapy for
breast cancer in 1986 (Hryniuk & Levin, 1986). The same
authors subsequently analysed 65 groups of patients treated
with chemotherapy for advanced ovarian carcinoma and sug-
gested a correlation between dose intensity of chemotherapy,
clinical response and median survival time (Levin & Hryniuk,
1987). However, this study was retrospective, and some of
the trials using the highest dose intensities were from tertiary
referral centres, where patient selection might have had a
major influence on outcome. In addition, the authors
analysed only planned and not received ARDI. Since those
patients who were entered into high dose studies were likely
to have been more stringently selected and the dose delivered
is unknown, the significance of the observed correlation is
uncertain.
Randomised trials of single agent versus combination
chemotherapy in general show no major survival difference
(Gynaecological Group: Clinical Oncology Society of Austra-
lia, 1986; Williams et al., 1987), although there is a
significantly higher response rate. Of 35 such trials in the past
10 years, three reported a survival advantage for the com-
bination chemotherapy, one an advantage for single agent
therapy, the rest showing no significant difference (personal
communication: M. Palmer and L. Stewert). However, in
none of those studies are data or received ARDI presented.
In a recent study, Jacobs et al. (1988) have retrospectively
analysed the received dose intensity in a group of 71 patients
receiving cisplatin, doxorubicin and cyclophosphamide for
advanced ovarian carcinoma. Although a trend for improved
survival with high received dose intensity was observed, this
did not achieve statistical significance. O'Connell et al. (1987)
have prospectively assessed a high dose intensity regimen
comprising weekly doxorubicin and escalating cisplatin.
In this group of 37 patients, two had treatment related
deaths, and treatment was discontinued in four other patients
because of unacceptable toxicity. Prolonged marrow suppres-
sion occurred in two ofthese, and nephrotoxicity occurred in
another. Thus, the toxicity of the regimen compromised the
attainment of the projected dose intensity of the chemo-
therapy.
We have demonstrated a similar trend for this small group
of unselected patients to whom high dose intensity
chemotherapy was given. Of the 19 patients in the group,
three received two or less cycles of treatment due to toxicity
and four more failed to complete the planned six cycles of
treatment because of renal impairment or toxicity. In addi-
tion, 38 of 90 (42%) cycles of chemotherapy were given at
reduced dosage, or were delayed because of marrow suppres-
sion or transient reduction of creatinine clearance. As a
result, only one of 19 patients received chemotherapy at the
planned ARDI (and this patient developed progressive
disease on treatment).
Overall, the toxicity of the regimen was considerable, prob-
ably due in part to the relatively high median age of this
group compared with many studies of chemotherapy in
ovarian cancer. In addition to the renal impairment and
marrow toxicity (which produced an episode of neutropenic
sepsis in one patient), severe nausea and vomiting were seen
in all patients despite intensive anti-emetic therapy. Alopecia
was also invariable.
The most common long-term toxicity was severe peripheral
neuropathy which affected the majority of patients. This was
temporarily disabling in most. Four of the 11 patients
affected required a walking aid. However, it improved in all
patients and appeared to resolve in those surviving up to 9
months.
Clearly, the doses ofdrugs which can be given in high dose
intensity chemotherapy regimens are dictated by the dose-
limiting toxicities of each drug. In this study, cisplatin was
responsible for the major short-term (nephrotoxicity) and
long-term (peripheral neuropathy) toxicity of this regimen.
Such problems might be circumvented by the use of a
cisplatin analogue, particularly carboplatin. However, a
combination such as carboplatin and cyclophosphamide in
high dose would probably produce severe myelotoxicity.
Evidence from recent studies using haemopoietic growth fac-
tors with myelosuppressive chemotherapy have shown that
the duration and degree of drug induced neutropenia can be
significantly reduced by the use of such factors, and in some
cases a reduction in neutropenic sepsis has been documented
(Bronchud et al., 1988). Although such agents would clearly
be ofpotential advantage, the dose-limiting toxicity ofcarbo-
platin is thrombocytopenia, and none of the currently avail-
able recombinant haemopoietic growth factors have been
shown to produce significant improvement in platelet counts
in humans. Nevertheless, the use of such factors might allow
the dose of classical alkylating agents in such regimens to be
increased. An alternative method of achieving a higher dose
intensity is the inclusion of more drugs with differing dose-
limiting toxicities, as used in regimens such as CHAP. How-
ever, comparisons of two- and four-drug regimens are diffi-
cult, and a major criticism of Levin and Hryniuk's method of
calculating ARDI is that is assumes that all of the drugs in a
particular combination have equivalent anti-tumour activity.
In at least two studies (Barker & Wiltshaw, 1981; Gruppo
Interegionale Cooperativo Oncologico Ginecologia, 1987) the
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combinations failed to produce improved response rates or
survival.
Neijt et al. (1987), in a prospective randomised study, have
demonstrated that a cisplatin/cyclophosphamide (CP) com-
bination was equivalent to the CHAP-5 regimen in terms of
response, progression-free survival and overall survival.
Furthermore, although nephrotoxicity was more severe in the
CP arm, other toxicities, including myelosuppression and
neurotoxicity were more frequent in patients given the four-
drug combinations.
To attempt to overcome the problems of comparison of
such regimens, we have analysed the dose intensities in our
study using the CP regimen described above as the standard
with an ARDI of 1.0. Using this method, the planned ARDI
of our regimen is 1.5, and the median received ARDI is 1.18.
A direct comparison of the outcome for patients in our
study and the trial of Neijt et al. (1987) is, of course,
impossible. However, it is noteworthy that although the
received ARDI for our patients is higher than the planned
ARDI of CP in the study of Neijt et al. (and therefore higher
than their received ARDI - the percentages of total planned
doses given were 94% for cisplatin and 83% for cyclophos-
phamide), the overall response rates were identical, at 67%.
In view of the small number of patients, and short follow-
up, no comment can be made regarding the outcome for the
study group. The clinical CR rate (10/18) is disappointing,
but this may be because most patients had bulky disease
postoperatively. It is noteworthy that most had >2 cm
residual disease after laparotomy.
For those patients analysed for ARDI, a median value of
0.90 was attained, approaching the projected dose intensity
of the CHAP regimen. However, two of our patients had
received ARDIs of less than 0.4.
Prospective randomised studies of the effect of dose inten-
sity on survival in ovarian carcinoma are essential if the
effect of dose intensity is to be properly assessed. Based on
our results, we believe that an initial step in any such study
should be to test whether the high dose intensity chemo-
therapy can be delivered. Although we were unable to attain
the projected ARDI in this study, that achieved might be
suitable as the high intensity arm of a randomised study.
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